InvestorsHub Logo

JTORENCE

12/14/21 12:40 PM

#386147 RE: FatAlbert1986 #386145

FatAlbert1986' They sure do, just as we did with IPIX...

"THOSE THAT LIVE IN GLASS HOUSES, SHOULDN'T THROW STONES"

DaubersUP

12/14/21 1:43 PM

#386149 RE: FatAlbert1986 #386145

Maybe we get a PR stating the same for our Covid trial. Loooooooool

loanranger

12/14/21 1:45 PM

#386150 RE: FatAlbert1986 #386145

"The CRO made a mistake so now there’s a 16% decrease from placebo."

That's not what happened at all. Read it again.
There was a 16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) vs. placebo group (64%) before AND after the correction of the p-values.

So sad.

Lemoncat

12/14/21 1:54 PM

#386151 RE: FatAlbert1986 #386145


This secondary endpoint was a huge success:

56% relative reduction in the number of days of SOM in the avasopasem treatment group (8 days) vs. placebo group (18 days) (p=0.0022*) (previously reported as p=0.011) (secondary endpoint)

sox040713

12/14/21 4:18 PM

#386156 RE: FatAlbert1986 #386145

Leo - “Yes, they do.”

People really fall for this crap….